Barlow Wealth Partners Inc. Takes $184,000 Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Barlow Wealth Partners Inc. purchased a new position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 2,200 shares of the biopharmaceutical company’s stock, valued at approximately $184,000.

Several other institutional investors also recently bought and sold shares of the company. Amalgamated Bank lifted its stake in shares of Intra-Cellular Therapies by 117.3% in the second quarter. Amalgamated Bank now owns 6,922 shares of the biopharmaceutical company’s stock worth $474,000 after buying an additional 3,736 shares in the last quarter. Vanguard Personalized Indexing Management LLC boosted its stake in Intra-Cellular Therapies by 20.0% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 6,312 shares of the biopharmaceutical company’s stock valued at $432,000 after purchasing an additional 1,052 shares during the last quarter. Sei Investments Co. increased its holdings in shares of Intra-Cellular Therapies by 25.1% in the 2nd quarter. Sei Investments Co. now owns 160,487 shares of the biopharmaceutical company’s stock worth $10,992,000 after purchasing an additional 32,176 shares in the last quarter. Xponance Inc. raised its stake in shares of Intra-Cellular Therapies by 135.6% in the second quarter. Xponance Inc. now owns 13,329 shares of the biopharmaceutical company’s stock worth $913,000 after purchasing an additional 7,671 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in shares of Intra-Cellular Therapies during the second quarter valued at $34,178,000. 92.33% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently commented on ITCI shares. Piper Sandler reiterated a “neutral” rating and issued a $132.00 price objective (up from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Morgan Stanley lifted their price target on shares of Intra-Cellular Therapies from $92.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Royal Bank of Canada increased their price objective on shares of Intra-Cellular Therapies from $106.00 to $108.00 and gave the company an “outperform” rating in a research report on Friday, October 4th. Cantor Fitzgerald raised shares of Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 14th. Finally, Leerink Partnrs lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Six analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $100.31.

Intra-Cellular Therapies Trading Up 0.2 %

NASDAQ ITCI opened at $126.50 on Wednesday. The business’s fifty day moving average is $89.99 and its 200 day moving average is $81.30. Intra-Cellular Therapies, Inc. has a fifty-two week low of $62.78 and a fifty-two week high of $128.00.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). The company had revenue of $175.40 million for the quarter, compared to analysts’ expectations of $172.30 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The firm’s quarterly revenue was up 39.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.25) earnings per share. As a group, equities research analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Insider Buying and Selling at Intra-Cellular Therapies

In related news, CEO Sharon Mates sold 51,000 shares of Intra-Cellular Therapies stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the sale, the chief executive officer now owns 1,070,329 shares of the company’s stock, valued at approximately $91,834,228.20. This trade represents a 4.55 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, President Michael Halstead sold 22,869 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $89.12, for a total value of $2,038,085.28. The disclosure for this sale can be found here. Insiders own 2.60% of the company’s stock.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.